Keensight Capital is a European Growth Buyout investor specializing in Technology and Healthcare. The firm partners with the management teams of fast-growing, profitable companies, combining investment capital with strategic guidance and operational support to help businesses develop. Its approach is grounded in sector expertise and a focus on working alongside company leaders as growth partners.

Keensight invests in companies across a range of areas, including cybersecurity, financial and risk-management software, healthcare technology, regenerative medicine, data management, and analytics. Recent portfolio activity includes businesses such as Nomios, ACTICO, Bedfont Scientific, Isto Biologics, and Uve. The firm also shares perspectives on topics affecting its sectors, including the use of artificial intelligence in European healthcare.

Keensight reports more than 25 years of experience in Technology and Healthcare and over €8 billion in assets under management as of December 31, 2025. Its team represents 30 nationalities, and its investment tickets range from €10 million to €800 million. The firm presents its work through company partnerships, investment activity, sector insights, and portfolio stories.